Loading clinical trials...

Salivary C- Reactive Protein, Mean Platelet Volume and Neutrophil Lymphocyte Ratio as Diagnostic Markers for Neonatal Sepsis | Clinical Trials | Clareo Health

UNKNOWN

Salivary C- Reactive Protein, Mean Platelet Volume and Neutrophil Lymphocyte Ratio as Diagnostic Markers for Neonatal Sepsis

Salivary C-reactive Protein,Mean Platelet Volume and Neutrophil Lymphocyte Ratio as Diagnostic Markers for Neonatal Sepsis

NCT04800445•Cairo University

View on ClinicalTrials.gov

Summary

To evaluate reliability of salivary C-reactive protein ,mean platelet volume , neutrophil -lymphocyte ratio , and platelet lymphocyte ratio in diagnosis of neonatal sepsis

Eligibility

Age

0 - 0 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•\- Full term neonates of both genders from birth to the 28th day of life diagnosed with sepsis by history, clinical findings, laboratory findings, and blood culture. The clinical findings included the presence of three or more of the following:
•(1) temperature instability (hypothermia, hyperthermia) .
•(2) respiratory alterations (grunting, intercostal retractions, apnea, tachypnea, cyanosis) .
•(3) cardiovascular alterations (bradycardia, tachycardia, poor perfusion, hypotension) .
•(4) neurologic alterations (hypotonia, lethargy, seizures)
•(5) gastrointestinal alterations (feeding intolerance, abdominal distension). CRP values \>10 mg/L were considered to be positive.

Exclusion Criteria

•\- Preterm neonates .
•Neonates with CNS malformations, metabolic disorders, chromosomal abnormalities, intrauterine growth restriction, or birth asphyxia were excluded from the study

Locations (1)

Faculty of medicine

Cairo, Almanyal, Egypt

Key Dates

Start Date

April 4, 2020

Primary Completion Date

December 4, 2020

Completion Date

January 10, 2022

Last Updated

August 9, 2021

Enrollment

ACTUAL participants

Conditions

Neonatal Sepsis

Interventions

Salivary CRP

DIAGNOSTIC_TEST

Chlorhexidine Gluconate and Alcohol Hand Rubbing on Healthcare-associated Infection

NCT07421323

Neonatal Sepsis

View study

COMPLETEDPHASE4

Individualized Duration of Antibiotic Treatment in Early Onset Infection in Newborns.

NCT05329701

Early-Onset Neonatal SepsisAntibiotic Side Effect

View study

COMPLETED

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 9, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Salivary C- Reactive Protein, Mean Platelet Volume and Neutrophil Lymphocyte Ratio as Diagnostic Markers for Neonatal Sepsis

Inclusion Criteria

Exclusion Criteria

Chlorhexidine Gluconate and Alcohol Hand Rubbing on Healthcare-associated Infection

Individualized Duration of Antibiotic Treatment in Early Onset Infection in Newborns.

Smart Discharges for Mom & Baby

Enrichment of Human Milk With Human and Bovine Milk-based Fortifiers for Very Preterm Infants: a Meta-analysis

Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric and Neonatal AKI

Role of Presepsin as a Novel Biomarker in Diagnosis of Neonatal Sepsis